Skip to main content

Table 2 Hazard ratios for psoriasis in the nationwide breast cancer cohort

From: Risk and predictors of psoriasis in patients with breast cancer: a Swedish population-based cohort study

  No. of PYs Any psoriasis Psoriasis vulgaris Palmoplantar pustulosis Arthropathic psoriasis
Total/case no. HR (95% CI) Case no. HR (95% CI) Case no. HR (95% CI) Case no. HR (95% CI)
Overall
 Matched reference cohort 1,666,038 280,854/2795 1.00 (Ref.) 1234 1.00 (Ref.) 488 1.00 (Ref.) 433 1.00 (Ref.)
 Breast cancer cohort 307,684.8 56,235/599 1.17 (1.07–1.28) 298 1.33 (1.17–1.52) 95 1.04 (0.84–1.30) 75 0.94 (0.73–1.20)
Time since diagnosis
0 to < 0.5 year
  Matched reference cohort 139,886.5 280,854/238 1.00 (Ref.) 86 1.00 (Ref.) 48 1.00 (Ref.) 51 1.00 (Ref.)
  Breast cancer cohort 27,780.35 56,235/50 1.08 (0.80–1.47) 23 1.35 (0.85–2.14) 13 1.40 (0.76–2.59) 4 0.41 (0.15–1.13)
0.5 to < 1 year
  Matched reference cohort 138,587.1 278,473/228 1.00 (Ref.) 113 1.00 (Ref.) 27 1.00 (Ref.) 32 1.00 (Ref.)
  Breast cancer cohort 27,301.1 55,033/75 1.68 (1.30–2.19) 37 1.66 (1.15–2.41) 15 2.88 (1.52–5.43) 5 0.80 (0.31–2.07)
1–5 years
  Matched reference cohort 861,202.7 275,870/1451 1.00 (Ref.) 629 1.00 (Ref.) 281 1.00 (Ref.) 219 1.00 (Ref.)
  Breast cancer cohort 162,011.6 54,156/296 1.09 (0.96–1.24) 146 1.27 (1.06–1.52) 43 0.81 (0.58–1.12) 44 1.07 (0.77–1.48)
   > 5 years
  Matched reference cohort 526,362 159,147/878 1.00 (Ref.) 406 1.00 (Ref.) 132 1.00 (Ref.) 131 1.00 (Ref.)
  Breast cancer cohort 90,591.81 28,430/178 1.17 (0.99–1.38) 92 1.33 (1.06–1.68) 24 1.02 (0.66–1.60) 22 0.98 (0.62–1.56)
Age at breast cancer diagnosis
20–44 years
  Matched reference cohort 158,527.2 25,361/185 1.00 (Ref.) 75 1.00 (Ref.) 30 1.00 (Ref.) 46 1.00 (Ref.)
  Breast cancer cohort 28,908.36 5099/43 1.35 (0.97–1.90) 24 1.88 (1.17–3.00) 6 1.08 (0.45–2.62) 6 0.82 (0.35–1.94)
45–54 years
  Matched reference cohort 389,187.5 61,404/707 1.00 (Ref.) 285 1.00 (Ref.) 155 1.00 (Ref.) 122 1.00 (Ref.)
  Breast cancer cohort 72,753.48 12,289/151 1.16 (0.97–1.38) 72 1.39 (1.07–1.81) 28 0.95 (0.63–1.43) 22 0.97 (0.61–1.53)
55–64 years
  Matched reference cohort 549,425.4 89,347/1067 1.00 (Ref.) 447 1.00 (Ref.) 213 1.00 (Ref.) 172 1.00 (Ref.)
  Breast cancer cohort 102,753.2 17,850/229 1.14 (0.99–1.32) 109 1.27 (1.03–1.58) 42 1.04 (0.74–1.45) 23 0.74 (0.47–1.15)
65–80 years
  Matched reference cohort 568,898.3 104,742/836 1.00 (Ref.) 427 1.00 (Ref.) 90 1.00 (Ref.) 93 1.00 (Ref.)
  Breast cancer cohort 103,269.8 20,997/176 1.16 (0.99–1.38) 93 1.27 (1.01–1.59) 19 1.21 (0.73–2.01) 24 1.30 (0.82–2.07)
  1. CI confidence interval, no. number, PYs person-years, HR hazard ratio
  2. Hazard ratio of psoriasis in the nationwide breast cancer cohort compared to age, residence place, and social economic status matched Swedish female population (age 20–80). Significant associations are denoted in boldface. P values for the test of interaction term of breast cancer diagnosis and age groups are 0.84, 0.49, 0.91, and 0.37, respectively, for psoriasis overall, psoriasis vulgaris, palmoplantar pustulosis, and arthropathic psoriasis